Abstract:Qingxia Lin, 1 Jinrong Zhu, 2 Xuelei Gao 3 1 Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China; 2 Department of Central Pharmacy, Zhucheng People's Hospital, Weifang, Shandong, People's Republic of China; 3 Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China Correspondence: Xuelei Gao, Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China, Email Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases. Keywords: vitiligo, systemic lupus erythematosus, tofacitinib, JAK inhibitors Vitiligo is a common skin depigmentation disorder that significantly impacts patients' appearance and quality of life. With a prevalence rate of 0.5–2%, 1 vitiligo is easy to diagnose and difficult to treat. Current understanding suggests that vitiligo is an autoimmune disease characterized by the dysregulation of the adaptive immune response. 2 Increasing studies have shown that CD8+ T cells and the cytokines they secrete, notably interferon-γ (IFN-γ), by activating the JAK-STAT pathway, appear to play a pivotal role in the autoimmunity of vitiligo. 3 Tofacitinib, an oral Janus kinase (JAK) inhibitor, demonstrates the ability to inhibit lymphocyte-mediated damage to melanocytes by blocking the JAK-STAT signaling pathway. 3 Based on this mechanism of action, we hypothesize that JAK inhibitors hold promise as targeted therapeutic agents for vitiligo. We report a case of vitiligo combined with SLE, who quickly re-pigmented after treatment with tofacitinib and experienced no adverse reactions. It is reported as follows. A 56-year-old female with stably controlled SLE was diagnosed 10 years prior and currently taking 5 mg/d oral prednisone. She followed up at the rheumatology clinic every six months. One month prior, a white macular rash appeared on the patient's forehead with a rapidly expanding area. Dermatological examination revealed a white patch on the forehead measuring approximately 2.5cm×1.5 cm with clear borders (Figure 1). Reflectance confocal microscopy (RCM) revealed complete depigmentation of the basal layer of the epidermis (Figure 2). The final diagnosis was vitiligo. Relevant imaging and laboratory tests were performed, including frontal and lateral chest radiographs, electrocardiography, complete blood count, liver function tests, kidney function tests, plasma lipid levels, D-dimer, erythrocyte sedimentation rate, rheumatoid factor, antinuclear antibodies, anti-dsDNA antibodies, complements, thyroid antibody, immunoglobulins, antibodies to various infectious diseases such as syphilis, hepatitis B, hepatitis C, HIV, tumor markers such as CEA, CA199, AFP, and PPD test; no significant abnormalities were observed. Considering that the patient is currently using glucocorticoids to treat SLE, and she refused to add the dose of glucocorticoid to treat vitiligo. After obtaining the patient's written informed consent, the patient was given 10 mg/d oral tofacitinib, without the combination of phototherapy and topical medication. After 30 days, the white macular rash was completely re-pigmented (Figure 3), the pigment granules in the basal layer of the epidermis returned to normal on RCM (Figure 4), and no significant abnormalities were found on imaging and laboratory examination, including frontal and lateral chest radiographs, complete blood count, liver function tests, kidney function tests, plasma lipid levels, D-dimer, hepatitis B, and PPD test. No recurrence was observed at the 6-month follow-up, and the condition of SLE is stable. Figure 1 Before treatment, approximately 2.5cm × 1.5 cm white patches on the patient's forehead. Figure 2 Before treatment, reflectance confocal microscopy (RCM) revealed complete depigmentation -Abstract Truncated-

Vitiligo‐like Depigmentation Associated with Xuesaitong Capsule Treatment

A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib

Cutaneous adverse events under new clinical therapies: drug-induced vitiligo-like depigmentation

Symmetrical drug-related intertriginous and flexural exanthema/baboon syndrome induced by traditional Chinese medicine

Combination of total glucosides of paeony, narrow‐band ultraviolet B, and oral corticosteroid mini‐pulse therapy for nonsegmental vitiligo: A retrospective study

Erzhiwan Ameliorates Restraint Stress- and Monobenzone-Induced Depigmentation in Mice by Inhibiting Macrophage Migration Inhibitory Factor and 8-Hydroxy-2-Deoxyguanosine

A clinical evaluation of topical tacrolimus treatment for patients with vitiligo

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data

Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response

Successful Treatment of Vitiligo with Cold Atmospheric Plasma‒Activated Hydrogel

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report

Efficacy and safety of compound glycyrrhizin in combination with conventional therapy in treatment of vitiligo: A systematic review and meta-analysis of randomized controlled trials

Vitiligo nonsurgical treatment: a review of latest treatment researches

Vitiligo Treatment : A Review of Latest Treatment Researches

Mechanism of Action of a Chinese Herbal Compound Containing Quercetin, Luteolin, and Kaempferol in the Treatment of Vitiligo Based on Network Pharmacology and Experimental Verification

Simvastatin Ointment in the Treatment of Seven Childhood Diffuse Plane Xanthomas

Resistant Vitiligo Treated with Tofacitinib and Sustained Repigmentation after Discontinuation

A Systematic Study of Yiqi Qubai Standard Decoction for Treating Vitiligo Based on UPLC-Q-TOF/MS Combined with Chemometrics, Molecular Docking, and Cellular and Zebrafish Assays

Imiquimod-induced Localized Vitiligo in Wife and Lichen Planus in Husband.

The Treatment of Vitiligo with Liver and Kidney Deficiencies